HMTXF Stock Price and Chart — OTC:HMTXF — TradingView

Overview

Financials News Ideas Discussions Technicals Seasonals

HMTXF chart

HMTXF upcoming earnings

Key stats

About HEMOSTEMIX INC

Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The firm's, ACP-01, lead clinical stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. The company was founded by Roger Bergersen and Thomas A. Smeenk in 2006 and is headquartered in Calgary, Canada.

Financials

Performance

Revenue to profit conversion

Debt level and coverage

Earnings

Next:—

‪0.00‬

Ideas

See all ideas

Technicals

Summarizing what the indicators are suggesting.

Oscillators

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Oscillators

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Summary

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Summary

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Summary

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Moving Averages

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Moving Averages

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Seasonals

Displays a symbol's price movements over previous years to identify recurring trends.

The current price of HMTXF is 0.0565 USD — it has increased by 2.91% in the past 24 hours. Watch Hemostemix Inc stock price performance more closely on the chart.

Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Hemostemix Inc stocks are traded under the ticker HMTXF.

HMTXF stock has fallen by −8.35% compared to the previous week, the month change is a −27.56% fall, over the last year Hemostemix Inc has showed a 4.63% increase.

HMTXF reached its all-time high on Jan 7, 2016 with the price of 272.0000 USD, and its all-time low was 0.0240 USD and was reached on Jul 22, 2024. View more price dynamics on HMTXF chart.
See other stocks reaching their highest and lowest prices.

HMTXF stock is 2.83% volatile and has beta coefficient of −0.13. Track Hemostemix Inc stock price on the chart and check out the list of the most volatile stocks — is Hemostemix Inc there?

Today Hemostemix Inc has the market capitalization of ‪7.09 M‬, it has decreased by −1.55% over the last week.

Yes, you can track Hemostemix Inc financials in yearly and quarterly reports right on TradingView.

Hemostemix Inc is going to release the next earnings report on Nov 26, 2024. Keep track of upcoming events with our Earnings Calendar.

HMTXF net income for the last quarter is ‪−379.48 K‬ USD, while the quarter before that showed ‪−351.04 K‬ USD of net income which accounts for −8.10% change. Track more Hemostemix Inc financial stats to get the full picture.

No, HMTXF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.

Like other stocks, HMTXF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Hemostemix Inc stock right from TradingView charts — choose your broker and connect to your account.

Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Hemostemix Inc technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Hemostemix Inc stock shows the sell signal. See more of Hemostemix Inc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.